Ashland to Sell Nutraceuticals Business to Turnspire Capital Partners

US specialty chemicals producer Ashland has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. Financial details of the transaction were not given.

Ashland's nutraceuticals business, the company stated, supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well as custom formulation and contract manufacturing capabilities for the nutrition market, from four production facilities in New Jersey and Utah in the US, and Tamaulipas, Mexico.

“The nutraceuticals business has a strong portfolio of proprietary ingredients, formulation and manufacturing capabilities, and a dedicated team that has demonstrated a passion to grow over the years,” said Guillermo Novo, CEO of Ashland.

On the occasion of an update on the company’s fiscal 2023 fourth-quarter and full-year earnings on Nov. 1, 2023, Ashland announced its plan to initiate portfolio-optimization actions to further strengthen its resilience and improve profitability. One of these actions was the start of a divestiture process for the company’s nutraceuticals business.

© Shutterstock / PhotobyTawat
© Shutterstock / PhotobyTawat

Company

Ashland Inc.

500 Hercules Road
19808 Wilmington
US

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis